Skip to main content
. 2022 Nov 20;30(1):70–79. doi: 10.1097/GME.0000000000002095

Table 2.

Reasons for initiating and modifying select prescription and nonprescription treatments for symptoms associated with menopause

Noncompounded estrogen/progestogen (n = 202) Systemic estrogen
(n = 188)
Paroxetine
(n = 32)
Venlafaxine
(n = 29)
Black cohosh
(n = 190)
Top reasons for treatment initiation, n (%)
 Considered to have good efficacy 100 (49.5) 84 (44.7) 14 (43.8) 15 (51.7) 41 (21.6)
 Patient beliefs/perceptions 50 (24.8) 49 (26.1) 7 (21.9) 5 (17.2) 94 (49.5)
 HCP recommendation 85 (42.1) 78 (41.5) 11 (34.4) 10 (34.5) 18 (9.5)
 Consideration of potential adverse effects 31 (15.3) 17 (9.0) 5 (15.6) 6 (20.7) 12 (6.3)
 Advice/experience of family and/or friends 24 (11.9) 27 (14.4) 2 (6.3) 5 (17.2) 51 (26.8)
Treatment modification made, n/N (%) 34/202 (16.8) 36/188 (19.1) 7/32 (21.9) 11/29 (37.9) 52/190 (27.4)
 Dose adjusted 21/34 (61.8) 27/36 (75.0) 4/7 (57.1) 10/11 (90.9) 7/52 (13.5)a
  Dose increased 17/34 (50.0) 22/36 (61.1) 4/7 (57.1) 10/11 (90.9)
  Dose reduced 4/34 (11.8) 5/36 (13.9) 0 0
 Treatment switch 3/34 (8.8) 4/36 (11.1) 2/7 (28.6) 0 0
 Treatment added 1/34 (2.9) 3/36 (8.3) 0 0 0
 Other/switch to PO 2/34 (5.9) 0 0 0 0
 Medication discontinued 8/34 (23.5) 2/36 (5.6) 1/7 (14.3) 1/11 (9.1) 45/52 (86.5)
Reason for treatment modification, n/N (%)
 Lack of efficacy 15/34 (44.1) 22/36 (61.1) 7/7 (100.0) 8/11 (72.7) 38/52 (73.1)
 Patient decision 13/34 (38.2) 8/36 (22.2) 0 1/11 (9.1) 14/52 (26.9)
 Tolerability/AEs 4/34 (11.8) 1/36 (2.8) 2/7 (28.6) 0 0
 Consideration for potential AEs 3/34 (8.8) 2/36 (5.6) 0 1 (9.1) 0
 Duration of therapy 1/34 (2.9) 2/36 (5.6) 0 1 (9.1) 0
 Financial concerns 2/34 (5.9) 1/36 (2.8) 0 0 4/52 (7.7)
 HCP recommendation 7/34 (20.6) 2/36 (5.6) 0 4/11 (36.4) 5/52 (9.6)

AE, adverse event; HCP, health care provider.

aCaptured only as a “dose adjustment.”